Sweden's Vimian Q3 revenue rises 15%, beats estimates

By Reuters News


Overview

  • Sweden animal health group's Q3 revenue rose 15%, beating analyst expectations

  • Adjusted EBITA for Q3 grew 14% and beat analyst expectations

  • Company signed acquisition of Norfolk Medical Products after quarter end


Outlook

  • Vimian did not provide specific financial guidance for the current or future periods in its press release


Result Drivers

  • ORGANIC GROWTH - Co said double-digit organic revenue growth of 11% drove Q3 results

  • NICHE FOCUS - Co attributed outperformance to focus on attractive market niches and strong brand portfolio, per CEO Alireza Tajbakhsh


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

EUR 120.3 mln

EUR 115.94 mln (6 Analysts)

Q3 Adjusted EPS

EUR 0.02

Q3 Net Income

EUR 9.30 mln

Q3 Adjusted EBITA

Beat

EUR 29.2 mln

EUR 28.25 mln (4 Analysts)

Q3 Operating Profit

EUR 20.50 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

  • Wall Street's median 12-month price target for Vimian Group AB is SEK40.00, about 5.1% above its October 21 closing price of SEK38.05

  • The stock recently traded at 29 times the next 12-month earnings vs. a P/E of 23 three months ago


Reuters Recommended Reads

  • Oct 19 - France's Virbac Q3 revenue rises on strength in Both Companion Animal, Farm Animal segments

  • Oct 22 - Sweden's XVIVO Q3 revenue beat expectations on thoracic sales

  • Oct 22 - Sweden's Arjo Q3 revenue beats estimates, gross margin expands


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.